Li Jiu-Ke, Wei Fang, Jin Xiao-Hong, Dai Yuan-Min, Cui Hu-Shan, Li Yu-Min
Department of Ophthalmology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China.
Int J Ophthalmol. 2015 Dec 18;8(6):1202-6. doi: 10.3980/j.issn.2222-3959.2015.06.22. eCollection 2015.
To evaluate the relationship between intravitreal bevacizumab (IVB) treatment and the levels of vitreous vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and vitreous-retina surface fibrosis in patients with proliferative diabetic retinopathy (PDR).
This study was a prospective, open-label, controlled, randomized clinical trial. Sixty-eight eyes of PDR patients (n=53) and macular hole patients (n=15) were enrolled in this study. Thirty-four eyes of the PDR patients received IVB before vitrectomy. Twenty-three of the 34 PDR patients received IVB treatment 5d before vitrectomy (subgroup a), and 11 of the 34 PDR patients received IVB treatment greater than 2wk prior to vitrectomy (subgroup b). Nineteen of the PDR patients did not receive IVB treatment at any time prior to vitrectomy. The levels of bFGF and VEGF in vitreous samples were measured using enzyme-linked immunosorbent assay (ELISA) and the degree of vitreoretinal fibrosis was characterized using clinical data and data obtained intra-operatively.
In PDR patients, VEGF and bFGF levels were significantly increased compared to non-PDR (control) subject's eyes (P<0.01). In PDR patients, vitreous VEGF levels were significantly decreased following IVB treatment compared to PDR patients that did not receive IVB treatment (P<0.01). The degree of vitreoretinal fibrosis was significantly increased in subgroup b compared to subgroup a(P<0.05) and to patients that did not receive IVB (P<0.05). Vitreous bFGF levels were significantly greater in subgroup b than subgroup a (P<0.01) or in patients who did not receive IVB treatment (P<0.05). A Spearman's rank correlation test indicated that higher levels of vitreous bFGF, but not VEGF, correlated with the degree of vitreoretinal fibrosis.
We found that bFGF levels increase in PDR patient's vitreous after IVB treatment longer than two weeks prior to vitrectomy and correlated with the degree of fibrosis after IVB treatment. These findings suggest vitreous fibrosis is increased in PDR patients after IVB treatment may be due to increased levels of bFGF.
评估玻璃体内注射贝伐单抗(IVB)治疗与增殖性糖尿病视网膜病变(PDR)患者玻璃体内血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)水平及玻璃体 - 视网膜表面纤维化之间的关系。
本研究为前瞻性、开放标签、对照、随机临床试验。纳入68只PDR患者眼(n = 53)和黄斑裂孔患者眼(n = 15)。34只PDR患者眼在玻璃体切除术前接受IVB治疗。34例PDR患者中,23例在玻璃体切除术前5天接受IVB治疗(a组),11例在玻璃体切除术前超过2周接受IVB治疗(b组)。19例PDR患者在玻璃体切除术前未接受任何IVB治疗。采用酶联免疫吸附测定(ELISA)测量玻璃体液样本中bFGF和VEGF水平,并使用临床数据和术中获得的数据对玻璃体视网膜纤维化程度进行特征描述。
与非PDR(对照)受试者的眼睛相比,PDR患者的VEGF和bFGF水平显著升高(P < 0.01)。与未接受IVB治疗的PDR患者相比,IVB治疗后PDR患者的玻璃体内VEGF水平显著降低(P < 0.01)。与a组相比,b组的玻璃体视网膜纤维化程度显著增加(P < 0.05),与未接受IVB治疗的患者相比也显著增加(P < 0.05)。b组的玻璃体内bFGF水平显著高于a组(P < 0.01)或未接受IVB治疗的患者(P < 0.05)。Spearman等级相关检验表明,玻璃体内较高水平的bFGF而非VEGF与玻璃体视网膜纤维化程度相关。
我们发现,在玻璃体切除术前超过两周接受IVB治疗的PDR患者玻璃体内,bFGF水平升高,且与IVB治疗后的纤维化程度相关。这些发现表明,IVB治疗后PDR患者的玻璃体纤维化增加可能是由于bFGF水平升高所致。